Synthesis and Evaluation of the Neurotropic Activity of New Tetrahydropyridazin-3-one Derivatives

R. Dzh. Khachikyan; Хачикян Рая Джаановна; Z. G. Hovakimyan; Овакимян Заруи Грантовна; G. A. Panosyan; Паносян Генрик Артаваздович; L. S. Mirzoyan; Мирзоян Лилит Самвеловна; R. G. Paronikyan; Пароникян Рузанна Гарниковна

doi:10.31857/S0514749224110103

Synthesis and Evaluation of the Neurotropic Activity of New Tetrahydropyridazin-3-one Derivatives

Authors: Khachikyan R.D.¹, Hovakimyan Z.G.¹, Panosyan G.A.¹, Mirzoyan L.S.¹, Paronikyan R.G.¹
Affiliations:
1. The Institut of Organic Chemistry of the Scientific Technological Centre of Organic and Pharmaceutical Chemistry of NA S of Republic of Armenia
Issue: Vol 60, No 11 (2024)
Pages: 1159-1164
Section: Articles
URL: https://rjeid.com/0514-7492/article/view/682502
DOI: https://doi.org/10.31857/S0514749224110103
EDN: https://elibrary.ru/QHGOZX
ID: 682502

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

It was established that 4-aryl-4-oxo-2-indol-3-yl butanoic acid and its derivatives upon interaction with hydrazine form 6-aryl-4-[(unsubstituted and substituted) indol-3-yl]-2, 3, 4, 5-tetrahydropyridazin-3-ones, while similarly constructed 4-aryl-4-oxo-2-heterylbutanoic acids under similar conditions are heterocyclized with subsequent azole elimination, resulting in the formation of 6-aryl-2,3-dihydropyridazin-3-ones. The study of the neurotropic activity of new tetrahydropyridazinones derivatives showed that all of the studied substances have anxiolytic action.

Keywords

β-aroylacrylic acid, heterocyclization, indole, neurotropic activity, pyridazinone

Full Text

References

Nada A., Zayed M. F. and Gad W., Egypt. J. Chem., 1985, 28, 527–530. doi: 10.1002/chin.198801240
Хачикян Р. Дж., Карамян Н. В., Паносян Г. А., Инджикян М. Г. Изв. РАН, Сер. хим. 2004, 8, 1982–1986. doi: 10.1007/s11172-006-0068-7
Хачатрян Р.А., Хачикян Р.Дж., Карамян Н.В. Паносян Г. А., Инджикян М. Г. ХГС, 2004, 40 (4), 446–451. doi: 10.1023/B:COHC.0000033535.93962.f5
Kadi M., X. El’, Hashash M.A. El’, Sayed M.A. Rev. Roum. Chem. 1981, 26 (8), 1161–1165.
Asif M., Singh A., Khan S.A., Husain A. Braz. J. Pharm. Sci. 2018, 54, 1–12. doi: 10.1590/s2175-97902018000300040
Geiger W.B., Conn J.E. J. Am. Chem. Soc. 1945, 67 (1), 112–116. doi: 10.1021/ja01217a038
Cramer B.J., Schroeder W., Moran W.J., Nield C. H., Edwards M., Jarowski C. I., Puetzer B. J. Am. Pharm. Ass. Sci. Ed. 1948, 37, 439–449. doi: 10.1002/jps.3030371102
Worrall R.L. Med. World 1946, 2.
Bowden K., Dixon M.S., Ranson R.J. J. Chem. Res. 1979, 1, 8.
Хачикян Р.Дж., Овакимян З.Г., Карамян Э.О., Пароникян Р. В., Степанян Г. М., Балян А. А. Хим. ж. Армении 2017, 70 (3), 384–388.
Хачикян Р.Дж., Овакимян З.Г., Микаелян А.А., Пароникян Р. В., Степанян Г. М. Хим. фарм. ж. 2017, 51 (10), 85–88. doi: 10.30906/0023-1134-2017-51-10-22-25
Машковский М.Д., Лекарственные средства, М.: Новая волна. 2021, 1216–1218.
Dunham N.W., Miya T.S. J. Am. Pharm. Ass. Sci. 1957, 46 (3), 208–209. doi: 10.1002/jps.3030460322
Беленький М. Элементы количественной оценки фармакологического эффекта. Л.: Изд. Мед. литературы, 1963. 152–155.
Vogel H.G. and Vogel W.H. Psychjtropic and neurotropic activity In Drug Discovery and Evaluation Berlin–N.Y.: Springer. 2008, 569–874.
File Behav S.E., Brain. Res. 2001, 125, 151–157. doi: 10.1016/S0166-4328(01)00292-3
Stanford S.C. J. Psycopharmac. 2007, 21, 134–135.
Prut L., Berzung C. Eur. J. Pharmacol. 2003, 463, 3–33. doi: 10.1016/S0014-2999(03)01272-X
Pelow S., File S.E. Pharmacol. Biochem. Behav. 1986, 24 (3), 525–529. doi: 10.1016/0091-3057(86)90552-6